These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15512890)

  • 1. ALS combination treatment. Drug cocktails.
    Rosenfeld J
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():115-7. PubMed ID: 15512890
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic trials in ALS.
    Bradley W
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
    [No Abstract]   [Full Text] [Related]  

  • 3. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M; Swash M
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-drug therapy in amyotrophic lateral sclerosis: the case for a multi-drug approach.
    Rosenfeld J
    Muscle Nerve; 2004 Nov; 30(5):673-5. PubMed ID: 15452840
    [No Abstract]   [Full Text] [Related]  

  • 5. Baseline disease characteristics.
    Leigh PN
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():64-7. PubMed ID: 15512877
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials.
    de Carvalho M; Chio A; Dengler R; Hecht M; Weber M; Swash M
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Mar; 6(1):17-28. PubMed ID: 16036422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is next in ALS clinical trials?
    Sorenson EJ
    Neurology; 2007 Aug; 69(8):719-20. PubMed ID: 17709702
    [No Abstract]   [Full Text] [Related]  

  • 8. [The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis].
    Van den Bosch L
    Verh K Acad Geneeskd Belg; 2006; 68(4):249-69. PubMed ID: 17214440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALS trial design: expectation and reality.
    Miller RG; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():52-4. PubMed ID: 15512873
    [No Abstract]   [Full Text] [Related]  

  • 10. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
    Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
    J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-drug therapy in amyotrophic lateral sclerosis: combinations of multiple, untested drugs should not be used at this time.
    Shefner JM
    Muscle Nerve; 2004 Nov; 30(5):676-8. PubMed ID: 15452839
    [No Abstract]   [Full Text] [Related]  

  • 13. Can neurotrophic factors prevent or reverse motoneuron injury in amyotrophic lateral sclerosis?
    Appel SH; Smith RG
    Exp Neurol; 1993 Nov; 124(1):100-2. PubMed ID: 8282067
    [No Abstract]   [Full Text] [Related]  

  • 14. Classical and emergent measures for clinical trials in ALS.
    Miller RG
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S1-2. PubMed ID: 12396790
    [No Abstract]   [Full Text] [Related]  

  • 15. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
    Malta E
    Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of statistical MUNE in a multicenter clinical trial.
    Shefner JM; Cudkowicz ME; Zhang H; Schoenfeld D; Jillapalli D;
    Muscle Nerve; 2004 Oct; 30(4):463-9. PubMed ID: 15316983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revised statistical motor unit number estimation in the Celecoxib/ALS trial.
    Shefner JM; Cudkowicz ME; Zhang H; Schoenfeld D; Jillapalli D;
    Muscle Nerve; 2007 Feb; 35(2):228-34. PubMed ID: 17058270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.
    Ryu H; Smith K; Camelo SI; Carreras I; Lee J; Iglesias AH; Dangond F; Cormier KA; Cudkowicz ME; Brown RH; Ferrante RJ
    J Neurochem; 2005 Jun; 93(5):1087-98. PubMed ID: 15934930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of clinical therapeutic trials in amyotrophic lateral sclerosis.
    Brooks BR; Sufit RL; DePaul R; Tan YD; Sanjak M; Robbins J
    Adv Neurol; 1991; 56():521-46. PubMed ID: 1853781
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulatory issues in ALS clinical trials.
    Bryan WW
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():36-41. PubMed ID: 15512868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.